Adaptive Biotechnologies (ADPT) EBIAT: 2018-2025
Historic EBIAT for Adaptive Biotechnologies (ADPT) over the last 8 years, with Sep 2025 value amounting to $9.5 million.
- Adaptive Biotechnologies' EBIAT rose 129.74% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$79.6 million, marking a year-over-year increase of 59.23%. This contributed to the annual value of -$159.6 million for FY2024, which is 29.16% up from last year.
- Adaptive Biotechnologies' EBIAT amounted to $9.5 million in Q3 2025, which was up 137.27% from -$25.6 million recorded in Q2 2025.
- Adaptive Biotechnologies' EBIAT's 5-year high stood at $9.5 million during Q3 2025, with a 5-year trough of -$69.5 million in Q4 2023.
- Its 3-year average for EBIAT is -$39.2 million, with a median of -$46.2 million in 2024.
- Per our database at Business Quant, Adaptive Biotechnologies' EBIAT plummeted by 72.94% in 2023 and then soared by 129.74% in 2025.
- Over the past 5 years, Adaptive Biotechnologies' EBIAT (Quarterly) stood at -$61.4 million in 2021, then skyrocketed by 34.53% to -$40.2 million in 2022, then tumbled by 72.94% to -$69.5 million in 2023, then soared by 51.46% to -$33.7 million in 2024, then surged by 129.74% to $9.5 million in 2025.
- Its last three reported values are $9.5 million in Q3 2025, -$25.6 million for Q2 2025, and -$29.9 million during Q1 2025.